Finance

Lists
Why is CYTK down 2,15%?
Dive Deeper
CYTK:NASDAQ
Cytokinetics, Inc.
61,35 $
-2,15%
(-1,35) 1D
61,35 $
0,00% (0,00)
After hours
Closed: 6 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Open
62,20 $
High
62,52 $
Low
60,68 $
Mkt. cap
8,92 млрд
Avg. vol.
2,09 млн
Volume
3,23 млн
52-wk high
88,31 $
52-wk low
54,30 $
EPS
-7,22 $
Beta
0,41
Shares outstanding
139,02 млн
No. of employees
673
Open
62,20 $
High
62,52 $
Low
60,68 $
Mkt. cap
8,92 млрд
Avg. vol.
2,09 млн
Volume
3,23 млн
52-wk high
88,31 $
52-wk low
54,30 $
EPS
-7,22 $
Beta
0,41
Shares outstanding
139,02 млн
No. of employees
673
News stories
From web sources and news partners
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, Калифорния, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to CYTK in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current 61,35 $
146,00 $ (+137,98%)
Average
110,27 $ (+79,74%)
Lowest
85,00 $ (+38,55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
140,00 $
+128,2%
10/05/2026
Serge Belanger
Needham
Buy
Maintained
112,00 $
+82,6%
10/05/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
105,00 $
+71,1%
10/02/2026
Leonid Timashev
RBC Capital
Buy
Maintained
112,00 $
+82,6%
09/10/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
112,00 $
+82,6%
09/01/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
100,00 $
+63%
08/31/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
85,00 $
+38,5%
08/31/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
105,00 $
+71,1%
08/28/2026
Emily Field
Barclays
Buy
Reiterated
110,00 $
+79,3%
08/26/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
107,00 $
+74,4%
08/07/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
108,00 $
+76%
08/07/2026
Jason Butler
Citizens JMP
Buy
Maintained
110,00 $
+79,3%
08/07/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
146,00 $
+138%
07/31/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
103,00 $
+67,9%
07/23/2026
Eric Joseph
Citi
Buy
Maintained
99,00 $
+61,4%
07/16/2026
Ashwani Verma
UBS
Buy
Upgraded
115,00 $
+87,4%
06/29/2026
Salim Syed
Mizuho Securities
Buy
Maintained
118,00 $
+92,3%
06/23/2026
Unknown Analyst
Citi
Buy
Initiated
99,00 $
+61,4%
05/19/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
05/06/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
-
-
02/25/2026
Last report
2026 ж. 06 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
-1,50 $ / -1,61 $
+6,59%beat
Revenue / Est. (USD)
28,62 млн / 17,95 млн
+59,46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,94 млн
17,76 млн
19,36 млн
28,62 млн
Cost of goods sold
99,23 млн
104,40 млн
98,08 млн
103,40 млн
Cost of revenue
99,23 млн
104,40 млн
98,08 млн
103,40 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
69,46 млн
91,72 млн
104,90 млн
104,40 млн
Operating expense
69,46 млн
91,72 млн
104,90 млн
104,40 млн
Total operating expenses
168,69 млн
196,12 млн
202,97 млн
207,80 млн
Operating income
-166,76 млн
-178,37 млн
-183,62 млн
-179,17 млн
Other non operating income
-2,10 млн
14,20 млн
-100,00 м.
1,30 млн
EBT including unusual items
-306,18 млн
-183,03 млн
-206,03 млн
-198,76 млн
EBT excluding unusual items
-184,93 млн
-183,03 млн
-206,03 млн
-198,76 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-306,18 млн
-183,03 млн
-206,03 млн
-198,76 млн
Net profit margin
-15 814,98%
-1 030,87%
-1 064,48%
-694,39%
Earnings per share
-1,54
-1,50
-1,67
-1,50
Interest and investment income
10,25 млн
11,47 млн
11,02 млн
13,94 млн
Interest expense
-26,32 млн
-30,34 млн
-33,34 млн
-34,83 млн
Net interest expenses
-16,07 млн
-18,86 млн
-22,31 млн
-20,89 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-164,08 млн
-175,50 млн
-180,24 млн
-175,54 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары